ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Spondyloarthropathies"

  • Abstract Number: 2112 • ACR Convergence 2022

    Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study

    Christopher Ritchlin1, Philip J Mease2, Wolf-Henning Boehncke3, John Tesser4, Soumya Chakravarty5, Emmanouil Rampakakis6, May Shawi7, Elena Schiopu8, Joseph Merola9, Iain B McInnes10 and Atul Deodhar11, 1Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, 2Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 3Deptartment of Dermatology, Geneva University Hospitals, University of Geneva, Geneva, Switzerland, 4Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, 5Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, 6McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 7Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 8Michigan Medicine Rheumatology Clinic – Taubman Center, Ann Arbor, MI, 9Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 10Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, 11Oregon Health & Science University, Portland, OR, USA, Portland, OR

    Background/Purpose: Guselkumab (GUS) is associated with robust and sustained improvement in PsA signs and symptoms in subgroups of patients (pts) pooled from the phase 3…
  • Abstract Number: 0868 • ACR Convergence 2022

    Spondyloarthritis and Neonatal Factors Affecting the Gut Microbiome

    Joy Um1, Douglas Einstadter2, Myung-Yong Um3 and Maria Antonelli1, 1Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, 2Center for Health Care Research and Policy, Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, 3Department of Social Welfare, Sungkyunkwan University, Seoul, Republic of Korea

    Background/Purpose: Spondyloarthritis (SpA) consists of clinically and genetically related but phenotypically distinct disorders, including ankylosing spondylitis, enteropathic arthritis, psoriatic arthritis, reactive arthritis, and enthesitis-related arthritis…
  • Abstract Number: 1234 • ACR Convergence 2022

    Characterizing Imaging Phenotypes in PsA: The Effect of Age and Sex

    Lihi Eder1 and Kangping Cui2, 1Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada

    Background/Purpose: Musculoskeletal ultrasound (MSK-US) provides valuable information on disease phenotype in psoriatic arthritis (PsA). While age and sex are important determinants of health, limited information…
  • Abstract Number: 2114 • ACR Convergence 2022

    Early Clinical Improvement as Predictor of Long-term Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Guselkumab: Post Hoc Analysis Through 2 Years of a Phase 3 Study

    Iain B McInnes1, Enrique R Soriano2, Lai-shan Tam3, Natalie Shiff4, May Shawi5, Emmanouil Rampakakis6 and Jeffrey Curtis7, 1Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, 2Rheumatology Unit and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 3The Chinese University of Hong Kong, Hong Kong, China, 4Janssen Scientific Affairs, LLC; Community Health and Epidemiology, University of Saskatchewan, Philadelphia, PA, 5Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 6McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 7University of Alabama at Birmingham, Division of Immunology and Rheumatology, Birmingham, AL

    Background/Purpose: Patients (pts) with PsA experience lower quality of life than both the general population and pts with psoriasis alone1,2. Recent PsA treatment recommendations highlight…
  • Abstract Number: 0954 • ACR Convergence 2022

    What Drives the BASDAI in Pregnant Patients with Axial Spondyloarthritis? A Pooled Analysis of Four European Pregnancy Registries

    Yvette Meissner1, Nathalie Costedoat-Chalumeau2, Rebecca Fischer-Betz3, Frauke Foerger4, Anna Molto5, Marianne Wallenius6 and Anja Strangfeld1, 1Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, 2Inserm DR Paris 5, Paris, France, 3Uniklinik Duesseldorf, Duesseldorf, Germany, 4Inselspital Bern, Bern, Switzerland, 5Rheumatology Department, Cochin Hospital, APHP, Paris, France, 6St. Olav University Hospital, Trondheim, Norway

    Background/Purpose: The patient reported Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) includes the six components fatigue, neck, back or hip pain, pain or swelling in…
  • Abstract Number: 1250 • ACR Convergence 2022

    Physiologic Adaptive Change of the Patellar and Achilles Tendons: Sensitivity to Change Detected by Computer Analysis of Sequential Static Images

    CARLOS ANTONIO GUILLEN ASTETE, Africa Andreu Suarez and Marina Tortosa Cabanas, Ramon y Cajal University Hospital, Madrid, Spain

    Background/Purpose: Ultrasound studies stratify the results of the evaluations in ordinal degrees of intensity of findings dependent on the evaluator's opinion. Computer analysis of static…
  • Abstract Number: 2115 • ACR Convergence 2022

    Early Skin and Early Enthesitis Responses in Psoriatic Arthritis Patients Treated with Guselkumab Associate with Long-term Response: Post Hoc Analysis Through 2 Years of a Phase 3 Study

    Laura Coates1, Julio Ramírez2, Dennis McGonagle3, Sibel Aydin4, Miriam Zimmermann5, Francois Nantel6, May Shawi7, Emmanouil Rampakakis8, Peter Nash9 and Philip J Mease10, 1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, 2Arthritis Unit, Rheumatology Department, Hospital Clinic, Barcelona, Spain, 3University of Leeds, Leeds, UK, Leeds, United Kingdom, 4University of Ottawa, Ottawa Hospital Research Institute, Ottawa, ON, Canada, 5Immunology, Janssen Scientific Affairs, LLC, Zug, Switzerland, 6Nantel MedSci Consult, Montréal, QC, Canada, 7Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 8McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 9School of Medicine, Griffith University, Sunshine Coast, Australia, 10Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

    Background/Purpose: Guselkumab (GUS), an IL-23p19 inhibitor, has demonstrated efficacy in PsA across key Group for Research and Assessment of Psoriasis (PsO) and Psoriatic Arthritis (GRAPPA)-recommended…
  • Abstract Number: 0069 • ACR Convergence 2022

    Capturing Clinical Reasoning in Real Time Reveals Low Rate of Serious Adverse Reactions Requiring B/tsDMARD Discontinuation in Inflammatory Joint Disease: An Analysis of the OPAL Real-World Dataset

    Geoffrey Littlejohn1, Tegan Smith2, Sabina Ciciriello3, Peter Youssef4, Claire Deakin5, Nithila Anbumurali6 and Catherine OSullivan6, 1OPAL Rheumatology Ltd, Melbourne, Australia, 2OPAL Rheumatology Ltd, Geelong, Australia, 3Melbourne Health, Melbourne, Australia, 4University of Sydney, Sydney, Australia, 5OPAL Rheumatology Ltd, Mosman, Australia, 6OPAL Rheumatology Ltd, Sydney, Australia

    Background/Purpose: Routine management of inflammatory joint disease requires clinicians to consider an abundance of factors unique to each patient when deciding on the most appropriate…
  • Abstract Number: 1004 • ACR Convergence 2022

    SPARCC, MASES, LEI and MEI Indexes Capture Different Patients with Enthesitis in Axial Spondyloarthritis, Peripheral Spondyloartrhitis and Psoriatic Arthritis

    Raquel Granados1, lourdes Ladehesa-Pineda2, Maria Angeles Puche Larrubia3, Maxime Dougados4, Eduardo Collantes5 and Clementina Lopez-Medina6, 1Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Córdoba, Spain, 2Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain, 3Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Granada, Spain, 4Department of Rheumatology, Hôpital Cochin, Paris, France, Paris, France, 5IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, 6Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain

    Background/Purpose: Spondyloarthritis, (axial (axSpA), peripheral (pSpA)) and psoriatic arthritis (PsA)) share enthesitis as a hallmark clinical feature. Reliable clinical instruments have been developed to assess…
  • Abstract Number: 1253 • ACR Convergence 2022

    Gray Intensity Ratio Indices as a Method of Discrimination Between Changes Induced by Sport and by Spondyloarthritis in Load-bearing Entheses

    Marina Tortosa Cabanas, CARLOS ANTONIO GUILLEN ASTETE and Africa Andreu Suarez, Ramon y Cajal University Hospital, Madrid, Spain

    Background/Purpose: Computer analysis of radiological images has been recently introduced in the study of patients with musculoskeletal pathologies. Our research group has shown that this…
  • Abstract Number: 2129 • ACR Convergence 2022

    Serum Extracellular Matrix Biomarkers Identify Response to Guselkumab in Psoriatic Arthritis; Post-hoc Analysis from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years

    Signe Holm Nielsen1, Anne-Christine Bay-Jensen1, Peder Frederiksen1, Morten Karsdal1, May Shawi2, Soumya Chakravarty3, Alexa Kollmeier4, Warner Chen5 and Sheng Gao5, 1Nordic Bioscience, Herlev, Denmark, 2Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 3Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, 4Janssen-Cilag, Research & Development, LLC, San Diego, CA, 5Janssen Research and Development, LLC, Spring House, PA

    Background/Purpose: Psoriatic arthritis (PsA) is a progressive, joint-degenerative inflammatory disease with cartilage destruction, bone erosion and growth, and synovitis. Extracellular matrix (ECM) remodeling is also…
  • Abstract Number: 0129 • ACR Convergence 2022

    Effectiveness of Golimumab in the Treatment of Patients with Active Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis Who Failed Initial TNFα Therapy: A Pooled Analysis of European Prospective Observational Studies (the GO BEYOND Program)

    Marinella Govoni1, Anastas Batalov2, Dimitrios Boumpas3, Salvatore D'Angelo4, Filip De Keyser5, Rene-Marc Flipo6, Herbert Kellner7, Hermine Leroi8 and Ahmed Khalifa9, 1MSD Italy, Cento, Italy, 2Medical University of Plovdiv, Plovdiv, Bulgaria, 3National and Kapodistrian University of Athens, Heraklion, Greece, 4Rheumatology Department of Lucania - San Carlo Hospital of Potenza, Potenza, Italy, 5Department of Rheumatology, Ghent University Hospital, Maldegem, Belgium, 6CHU Lille, Boulogne-Billancourt, France, 7Schwerpunktpraxis für Rheumatologie und Gastroenterologie, Munich, Germany, 8MSD Belgium, Woluwe-Saint-Lambert, Belgium, 9MSD Sharp & Dohme GmbH, Germany, Kriens, Switzerland

    Background/Purpose: Patients with inflammatory arthritis often experience secondary non-response to a first-line tumor necrosis factor alpha inhibitor (TNFαi). GO-BEYOND is a study program comprised of…
  • Abstract Number: 1007 • ACR Convergence 2022

    Metabolic Disorders and Abnormal Dietary Patterns and Their Association with Psoriatic Arthritis Activity: The Dietary Intervention in PsA (DIPSA) Study

    Lihi Eder1, Charlene Compher2, Helen Emanoilidis3, Ryan F. Quinn2, Dafna Gladman4, Vinod Chandran5, Jose Scher6 and Alexis Ogdie7, 1Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, 2University of Pennsylvania, Philadelphia, PA, 3Women's College Hospital, Toronto, ON, Canada, 4Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 5Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, 6New York University School of Medicine, New York, NY, 7Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Psoriatic Arthritis (PsA) is associated with obesity and its related metabolic abnormalities. The role of diet as an adjunct therapy in PsA remains unclear.…
  • Abstract Number: 1255 • ACR Convergence 2022

    Rheumatologists Overcall Sacroiliitis on X-ray and MRI in Axial Spondyloarthritis Patients: Data from the BelGian Inflammatory Arthritis and SpoNdylitis cohorT (Be-GIANT)

    Ann-Sophie Kathleen De Craemer1, Manouk de Hooge2, Thomas Renson3, Liselotte Deroo4, Gaelle Varkas3, Liesbet Van Praet5, Rik Joos6, Jan Lenaerts7, Mieke Devinck8, Lieve Gyselbrecht9, isabelle peene3, Kristof Thevissen10, Philippe Carron3, Filip Van den bosch11 and Dirk Elewaut12, 1Ghent University Hospital, Gent, Belgium, 2Ghent University Hospital, Luxembourg, Luxembourg, 3Ghent University Hospital, Ghent, Belgium, 4Ghent University, Gent, Belgium, 5AZ Maria Middelares, Ghent, Belgium, 6Ghent University Hospital, Basel, Switzerland, 7Reuma Instituut Hasselt, Hasselt, Belgium, 8AZ Sint-Lucas, Brugge, Belgium, 9ASZ Aalst, Aalst, Belgium, 10Reumacentrum Genk, Genk, Belgium, 11Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, 12Department of Rheumatology, Ghent University Hospital, Belgium, VIB-UGent Center for Inflammation Research, Ghent University, Heusden, Belgium

    Background/Purpose: To investigate (1) agreement between local and central reading of sacroiliac joint images (X-ray and magnetic resonance imaging [MRI]) from axial spondylarthritis (axSpA) patients,…
  • Abstract Number: 2147 • ACR Convergence 2022

    Cumulative Dose and Exposure Time to Methotrexate Were Not Shown to Be Predictors of Hepatic Fibrosis by Elastography – A Monocentric Cohort Study

    Filipe Pinheiro1, Rui Gaspar2, Bruno Fernandes3, Armando Peixoto2, Guilherme Macedo2 and Iva Brito4, 1Rheumatology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, 2Gastroenterology Deparment, Centro Hospitalar e Universitário de São João, Porto, Portugal, 3Rheumatology Deparment, Centro Hospitalar e Universitário de São João, Porto, Portugal, 4Pediatric and Young Adult Rheumatology Unit, Centro Hospitalar Universitário de São João, Porto, Portugal

    Background/Purpose: Methotrexate is an immunomodulatory agentu sed in several inflammatory diseases, such as rheumatoid arthritis (RA), spondyloarthritis (SpA) or inflammatory bowel disease (IBD). Despite being…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 11
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology